Improved antigen cross-presentation by polyethyleneimine-based nanoparticles

International Journal of Nanomedicine

Volumn 6, Issue 1, 2011, Pages 77-84

  Chen, Jian ^a   Li, Zhengrong ^a   Huang, Hong ^b   Yang, Yanzhu ^b   Ding, Qian ^b   Mai, Junhua ^a   Guo, Wei ^b   Xu, Yuhong ^b  

^a School of Life Science and Biotechnology   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cross presentation; Dendritic cells; Polyethyleneimine; Vaccine

Indexed keywords

AMMONIUM CHLORIDE; CANCER VACCINE; CHLOROQUINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; OVALBUMIN; POLYETHYLENEIMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GEL ELECTROPHORESIS; IN VITRO STUDY; MOUSE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SCANNING ELECTRON MICROSCOPY; STATIC ELECTRICITY; ZETA POTENTIAL;

AMMONIUM CHLORIDE; ANIMALS; CELLS, CULTURED; CHLOROQUINE; CROSS-PRIMING; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; GENES, MHC CLASS I; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; PEPTIDE FRAGMENTS; POLYETHYLENEIMINE;

EID: 79251471424     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S15457     Document Type: Article

References (33)

1. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta. 2007; 1776(1):108-123.
2. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: An overview. Jpn J Clin Oncol. 2009;39(2):73-80.
3. Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br Med Bull. 2002;62:149-162.
4. Espinoza-Delgado I. Cancer vaccines. Oncologist. 2002;7 Suppl 3: 20-33.
5. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: Accomplishments and challenges. Crit Rev Oncol Hematol. 2008;67(2):93-102.
6. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
7. Guermonprez P, Amigorena S. Pathways for antigen cross presentation. Springer Semin Immunopathol. 2005;26(3):257-271.
8. Pavelic V, Matter MS, Mumprecht S, Breyer I, Ochsenbein AF. CTL induction by cross-priming is restricted to immunodominant epitopes. Eur J Immunol. 2009;39(3):704-716.
9. Nayak JV, Hokey DA, Larregina A, et al. Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells. J Immunol. 2006;177(12):8493-8503.
10. Stier EM, Mandal M, Lee KD. Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm 2005;2(1):74-82.
11. Bungener L, Serre K, Bijl L, et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine. 2002;20(17-18):2287-2295.
12. Kwon YJ, Standley SM, Goodwin AP, Gillies ER, Frechet JM. Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses. Mol Pharm. 2005;2(1):83-91.
13. Murthy N, Xu M, Schuck S, Kunisawa J, Shastri N, Frechet JM. A macromolecular delivery vehicle for protein-based vaccines: Acid- degradable protein-loaded microgels. Proc Natl Acad Sci U S A. 2003; 100(9):4995-5000.
14. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
15. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47-64.
16. Pan J, Zhang M, Wang J, et al. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett. 2004;94(1-2): 141-151.
17. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethyleniminemediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7(5):657-663.
18. Mann A, Richa R, Ganguli M. DNA condensation by poly-L-lysine at the single molecule level: Role of DNA concentration and polymer length. J Control Release. 2008;125(3):252-262.
19. Trentin D, Hubbell J, Hall H. Non-viral gene delivery for local and controlled DNA release. J Control Release. 2005;102(1):263-275.
20. Mannisto M, Ronkko S, Matto M, et al. The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment epithelial cell line. J Gene Med. 2005;7(4):466-476.
21. Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J Gene Med. 2002;4(5):536-547.
22. Shen H, Ackerman AL, Cody V, et al. Enhanced and prolonged crosspresentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1): 78-88.
23. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6(6): 715-726.
24. Yang YW, Hsu PY. The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens. Biomaterials. 2008;29(6):2516-2526.
25. Yan W, Chen W, Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release. 2008;130(1):22-28.
26. De Smedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res. 2000;17(2):113-126.
27. Savina A, Jancic C, Hugues S, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006;126(1):205-218.
28. Hotta C, Fujimaki H, Yoshinari M, Nakazawa M, Minami M. The delivery of an antigen from the endocytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells. Immunology. 2006;117(1):97-107.
29. Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med. 2005;202(6):817-828.
30. Tran KK, Shen H. The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Biomaterials. 2009; 30(7):1356-1362.
31. Garulli B, Stillitano MG, Barnaba V, Castrucci MR. Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin Vaccine Immunol. 2008;15(10):1497-1504.
32. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24(7):1121-1131.
33. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7(10):790-802.